Table 2.
Treatment characteristics of the study participants (n = 56)
| Treatment characteristic | n (%) |
|---|---|
| Treatment modality | |
| Systemic antineoplastic therapy | 26 (46.4) |
| HSCT conditioning | 24 (42.9) |
| Concurrent head and neck chemoradiotherapy | 5 (8.9) |
| Head and neck radiotherapy alone | 1 (1.8) |
| HSCT characteristics (n = 24) | |
| Autologous HSCT | 17 (70.8) |
| Allogeneic HSCT | 7 (29.2) |
| Myeloablative conditioning | 20 (83.3) |
| Reduced-intensity conditioning | 4 (16.7) |
| TBI | 1 (4.2) |
| Conditioning regimen (n = 24) | |
| Melphalan-based, without other conditioning agents | 10 (41.7) |
| Busulfan + fludarabine ± ATG | 7 (29.2) |
| Busulfan + melphalan | 5 (20.8) |
| BEAM | 1 (4.2) |
| Cyclophosphamide + busulfan | 1 (4.2) |
| Systemic antineoplastic therapy (n = 26) | |
| Treatment regimen/phase documented | 26 (100.0) |
| Days from last systemic treatment to retained assessmentMedian (IQR) | 10.5(5.25–13.5) |
| Range, days | 1–75 |
| Head and neck radiotherapy (n = 6) | |
| Concurrent systemic therapy | 5 (83.3) |
| Radiotherapy alone | 1 (16.7) |
| 35 prescribed fractions | 5 (83.3) |
| 29 prescribed fractions | 1 (16.7) |
| Cumulative RT dose at retained assessment (n = 6) | |
| 20 Gy | 1 (16.7) |
| 24 Gy | 1 (16.7) |
| 33.75 Gy | 1 (16.7) |
| 70 Gy | 3 (50.0) |
Percentages within HSCT and radiotherapy sections use their respective subgroup denominators. ATG antithymocyte globulin; BEAM, carmustine, etoposide, cytarabine, and melphalan, HSCT hematopoietic stem cell transplantation, IQR interquartile range, RT radiotherapy, TBI total-body irradiation